Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Alana on +44 1494 818 020 or alana@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Alana McKenna
Senior Account Manager
alana@zenopa.com
+44 1494 818 020

Testimonials
I just wanted to express my thanks for all the help and guidance Zenopa have provided me with over the past month. Zenopa have been very helpful throughout the interview and negotiation stages.
Allira, 2012

Johnson and Johnson names next CEO

22 February 2012 00:00 in Medical Company Restructures


Johnson and Johnson has announced that Alex Gorsky will be appointed as the company's next chief executive officer (CEO) on April 26th 2012.

Mr Gorsky is the current vice-chairman of the company's executive committee responsible for its medical devices and diagnostics group, as well as its global supply chain, healthcare compliance and privacy, and government affairs and policy.

He joined Johnson and Johnson in 1988 and has served in a variety of leadership roles across its various operations, as well as leading Novartis' US pharmaceuticals business for four years during a spell away from his current employer.

Mr Gorsky will take over the CEO role from Bill Weldon, who will also relinquish his post as chairman of the executive committee, though he will remain chairman of the board of directors.

Jim Cullen, independent presiding director of the board, said: "It is a testament to the leadership development and succession planning process at Johnson and Johnson that Mr Gorsky, like all of the previous chief executives in the company's 126-year history, was appointed from within the organisation."

Last month, the company announced its financial results for 2011, during which it experienced year-on-year growth of 5.6 percent.ADNFCR-8000103-ID-801299640-ADNFCR

Other news stories from 22/02/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd